Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, issued a correction to its April 28, 2026 press release regarding its partnership with TARA Mind. The correction clarifies that references to Veterans Exploring Treatment Solutions (VETS) were removed from earlier paragraphs, while reaffirming that the collaboration is aligned with a recent executive order aimed at advancing mental health treatments and expanding clinical research participation.
The partnership with TARA Mind is intended to support Phase 3 recruitment for Helus Pharma’s HLP003 program in major depressive disorder (MDD) and to expand outreach in veteran communities. HLP003 is a proprietary novel serotonergic agonist (NSA) that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) and is currently in Phase 3 clinical development for the adjunctive treatment of MDD.
Helus Pharma, the commercial operating name of Cybin Inc., is dedicated to developing synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s pipeline includes HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder, alongside an extensive research portfolio of investigational NSAs. The company operates in Canada, the United States, the United Kingdom, and Ireland.
Investors and stakeholders can access the full corrected press release at https://ibn.fm/re8HL. For more information about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. Latest news and updates regarding the company are available at https://ibn.fm/HELP.
The correction underscores the importance of accurate communication in clinical-stage pharmaceutical partnerships, especially those involving veteran communities and high-profile executive orders. The collaboration with TARA Mind remains focused on addressing the large unmet need in mental health treatments, particularly for depression and anxiety disorders. With the FDA Breakthrough Therapy Designation for HLP003, Helus Pharma is positioned to potentially offer durable improvements in mental health for patients who have not responded adequately to existing therapies.
This announcement is particularly significant given the ongoing efforts to improve mental health care access and clinical trial participation among veterans. The alignment with the executive order suggests a broader policy push to accelerate the development of innovative treatments. For Helus Pharma, the corrected press release clarifies the scope of its partnership while maintaining the strategic focus on advancing its NSA pipeline.
